
Forget needles, fat-jab PILLS are here: Why they're cheaper, how much weight you could lose & the side effects revealed
EVERYONE'S talking about fat jabs - the 'miracle' injections trimming inches off waistlines, and helping turn the tide on the obesity epidemic.
But what if there was an even easier - and cheaper - way than Ozempic -like injections, Wegovy and Mounjaro?
Science sits still for no slimmer and already, the next big thing is looming large on the horizon - and it could be as simple as popping a pill.
Slimming tablets have been around for decades, but now scientists want to harness the new momentum in obesity medicine - and use the billions being made from the jabs - to bring pills back with a bang.
Professor Jason Halford, of the European Association for the Study of Obesity, tells Sun Health: 'I think pills will eventually replace injections.
'People don't particularly like them and they're a bit afraid of injecting themselves.
'You've got to have the device, the needle, the sharps bin, it's got to be refrigerated, there are all sorts of challenges.
'If you can move it all to a tablet you can increase acceptance and hopefully it will be cheaper and become more widely available.'
Professor Richard Donnelly, editor of the medical journal Diabetes, Obesity and Metabolism, and clinical adviser at online weight loss clinic Juniper, agrees.
'Thirty years ago weight loss tablets had a terrible reputation and nobody really wanted to prescribe them,' he adds.
'They had rare but severe side effects and weren't particularly effective.
'Now there is a whole flood of development and a lot to be optimistic about.
Weight Loss Jabs - Pros vs Cons
'There is a big hope that developing pills will improve accessibility and cost less.'
There are several pills in development - some stimulate the same hormones as jabs to make us feel full, while others mimic bariatric surgery.
The end goal is the same - to do what willpower alone fails to achieve and stop us eating so much.
While some are yet to even be trialled in humans, one has already been submitted for approval in the US, meaning they could be available before the end of the year.
4
The most advanced pills being made are by the same companies behind the fat jabs.
Novo Nordisk, creator of Wegovy and Ozempic, has developed a tablet version of semaglutide, the active drug in those injections.
It applied for approval from the US Food and Drugs Administration last month.
Trials showed patients lost an average of 15 per cent of their bodyweight over 17 months on a 50mg daily dose, compared with eight per cent over 12 months on Wegovy.
Participants were three times more likely to achieve 'meaningful' weight loss when they were taking the pill, compared to those not taking the tablet.
Rival company Eli Lilly, which makes Mounjaro (tirzepatide) announced the results of its pill orforglipron in April.
The two drugs both work by stimulating GLP-1 hormones that make you feel full.
What are the other side effects of weight loss jabs?
Like any medication, weight loss jabs can have side effects.
Common side effects of injections such as Ozempic include:
Nausea: This is the most commonly reported side effect, especially when first starting the medication. It often decreases over time as your body adjusts.
Vomiting: Can occur, often in conjunction with nausea.
Diarrhea: Some people experience gastrointestinal upset.
Constipation: Some individuals may also experience constipation.
Stomach pain or discomfort: Some people may experience abdominal pain or discomfort.
Reduced appetite: This is often a desired effect for people using Ozempic for weight loss.
Indigestion: Can cause a feeling of bloating or discomfort after eating.
Serious side effects can also include:
Pancreatitis: In rare cases, Ozempic may increase the risk of inflammation of the pancreas, known as pancreatitis, which can cause severe stomach pain, nausea, and vomiting.
Kidney problems: There have been reports of kidney issues, including kidney failure, though this is uncommon.
Thyroid tumors: There's a potential increased risk of thyroid cancer, although this risk is based on animal studies. It is not confirmed in humans, but people with a history of thyroid cancer should avoid Ozempic.
Vision problems: Rapid changes in blood sugar levels may affect vision, and some people have reported blurry vision when taking Ozempic.
Hypoglycemia (low blood sugar): Especially if used with other medications like sulfonylureas or insulin.
Patients taking 36mg of orforglipron lost eight per cent of their bodyweight in 10 months, equating to 1st 2lbs from an average starting weight of 14st 3lbs – while participants taking a placebo lost just 3lbs.
It compares with 15 per cent weight loss in a year on Mounjaro.
Lilly said their pill 'could be readily manufactured and launched at scale for use around the world'.
But injections and pills have not been compared head-to-head yet.
Studies are ongoing and taking the science behind these game-changing jabs and applying it to tablets, does not guarantee success.
Pfizer abandoned the development of its drug lotiglipron in 2023 when a trial indicated potential liver damage as a side effect.
Drugs tend to be more easily absorbed by the body when they are injected directly into the bloodstream, compared to being digested through the gut.
And that's another key consideration - what the potential side effects of these new pills could be.
Unpleasant side effects were the downfall of the old generation of slimming pills.
4
The NHS has prescribed a pill called orlistat for years, dishing out £12million worth of it in England last year.
It works by preventing the gut from absorbing fat from food - but it means fat must be passed out in poo instead of digested.
This can lead to flatulence, more regular bowel movements and diarrhoea.
It can also cause bladder pains and breathing troubles - and weight loss doesn't match up to the jabs.
About eight in 10 patients suffer at least one side effect when using injections, most commonly tummy upset, according to trials.
Everything you need to know about fat jabs
Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases.
Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK.
Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market.
Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year.
How do they work?
The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight.
They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists.
They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high.
Can I get them?
NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics.
Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure.
GPs generally do not prescribe the drugs for weight loss.
Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk.
Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health.
Are there any risks?
Yes – side effects are common but most are relatively mild.
Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea.
Dr Sarah Jarvis, GP and clinical consultant at patient.info, said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.'
Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia.
Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health.
Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines.
Early data suggests pills might have similar rates.
Around six per cent of people taking any of Lilly or Novo Nordisk's pills or injections quit the medicines because of side effects.
Dr Leyla Hannbeck, of the Independent Pharmacies Association, says: 'The old generation drugs tended to be uncomfortable for a lot of people whereas these new ones are much more effective.
'All medicines will have side effects but the fact that the results are much better now means people are more willing to endure them.'
Prof Donnelly said he still does not expect new tablets to be as strong as jabs, adding: 'I don't think anybody believes these will cause the same level of weight loss that you might be reporting with Mounjaro.
'The flipside of that is that major weight loss might not all be good.
'Some of that might be muscle and if you lose 30 per cent of your body weight that is a fairly major transformation.
'Having an oral agent that reduces your weight by, say, 10 or 15 per cent, might actually be more sustainable, better tolerated and medically safer in some respects.'
While the GLP-1 tablets are likely to be first to market, inventors are also working on a daily pill that mimics the effects of gastric bypass surgery.
'GASTRIC BYPASS' PILL
US company Syntis Bio's offering, named Synt-101 creates a 24-hour lining in the gut that means food cannot be absorbed in the top six inches of the small intestine.
Rather, digestion is redirected to the lower areas of the gut, where hormones that tell the brain we are full, are triggered faster.
Working in a similar vein to surgery, it means patients feel fuller faster - and the lining is passed when the patient goes to the loo the next day.
Synt-101 has passed its first human safety tests and is expected to enter a full-scale clinical trial next year.
Another pill in development, Sirona, is made by UK-based Oxford Medical Products, and contains a 'dual polymer hydrogel' that expands in the stomach when it comes into contact with water.
It works like a gastric balloon, filling the patient's tummy making them feel full for hours, but is passed in their stools 'several days' later.
Early data from an NHS trial found patients lost 10 to 12 per cent in a year of treatment and there were no serious side effects.
Experts believe weight loss pills will serve a variety of purposes - as a follow-on treatment after stopping fat jabs, as an option for those who can't or don't want to use jabs and for people with less severe obesity, and less weight to lose.
There are hopes they will be less toxic than injections, which often cause side effects like stomach aches, vomiting or diarrhoea.
Weight regain after treatment is also an emerging issue with the jabs, which can currently only be prescribed for up to two years in the UK.
Rahul Dhanda, chief executive of Syntis Bio, said: 'Patients don't want to be stuck on a revolving door of injections and their side effects; they want to be on a manageable and sustainable weight loss path.
'Oral drugs that are simple, tolerable and safe will be the rational choice for maintenance therapy.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Sun
11 minutes ago
- The Sun
Tottenham clear decks for Thomas Frank as Spurs sack THREE of Ange Postecoglou's coaching team hours after boss axed
TOTTENHAM have sacked three members of Ange Postecoglou's coaching staff following the Aussie manager's dismissal yesterday. Postecoglou was relieved of his duties in North London yesterday despite leading Spurs to a first trophy in over 17 years this season. 5 5 5 The 59-year-old said his "overriding emotion is one of pride" following his dismissal, while Spurs claimed the decision to sack the former Celtic boss was one the "toughest" the board has had to make. Now the search for a new manager is underway and Spurs are already clearing the decks for their number one target - Brentford gaffer Thomas Frank. The Telegraph have revealed that Postecoglou's assistants Nick Montgomery, Sergio Raimundo and Mile Jedinak have all been axed too. However, senior assistant coach Matt Wells and goalkeeper coach Rob Burch have remained in their roles. Sporting director Johan Lange is leading the search for Spurs' new boss with Bees gaffer Frank, 51, thought to be the front-runner for the position. It's claimed that Frank is keen on taking the job at the Tottenham Hotspur Stadium and would want to bring members of his coaching staff along with him. Although the Dane is Spurs' preferred candidate, the club are reportedly "carefully assessing" their options with Fulham 's Marco Silva and Bournemouth 's Andoni Iraola also in the frame. It's widely understood that Spurs would have to fork out around £10m to release Frank from his current deal with Brentford, which runs until 2027. 5 5 Spurs have already had to splash the cash to get rid of Postecoglou, with the Aussie pocketing a rumoured £4m compensation fee on top of his £2m bonus for leading the club to Europa League glory. Sporting director Lange and Frank have history, with the pair coaching together at Danish club Lyngby and maintaining a good relationship since those days. Tottenham told fans in a statement that "news on the appointment of a new Head Coach will be announced in due course". Fans have hit back at Spurs for their decision to dismiss Postecoglou after winning the Europa League. While club is also facing a dressing room revolt with players more likely to leave after Postecoglou's exit, according to reports. But the Spurs hierarchy reiterated that they cannot base their decisions off their performance in just one competition. Their statement read: "Whilst winning the Europa League this season ranks as one of the club's greatest moments, we cannot base our decision on emotions aligned to this triumph. "It is crucial that we are able to compete on multiple fronts and believe a change of approach will give us the strongest chance for the coming season and beyond. "This has been one of the toughest decisions we have had to make and is not a decision that we have taken lightly, nor one we have rushed to conclude. "We have made what we believe is the right decision to give us the best chance of success going forward, not the easy decision." Ange Breaks Silence On Tottenham Sacking ANGE Postecoglou issued a statement just moments after being axed. It read: "When I reflect on my time as manager of Tottenham Hotspur, my overriding emotion is one of pride. "The opportunity to lead one of England's historic football clubs and bring back the glory it deserves will live with me for a lifetime. "Sharing that experience with all those who truly love this club and seeing the impact it had on them is something I will never forget. "That night in Bilbao was the culmination of two years of hard work, dedication and unwavering belief in a dream. "There were many challenges to overcome and plenty of noise that comes with trying to accomplish what many said was not possible. "We have also laid the foundations that means this club should not have to wait 17 more years for their next success. "I have enormous faith in this group of players and know there is much more potential and growth in them. I sincerely want to thank those who are the lifeblood of the club, the supporters. "I know there were some difficult times, but I always felt that they wanted me to succeed and that gave me all the motivation I needed to push on. "It's important to acknowledge the hard working people at Spurs who gave me encouragement on a daily basis. "And finally, I want to thank those who were with me every day for the last two years. "A fantastic group of young men who are now legends of this football club and the brilliant coaches who never once doubted we could do something special. 'We are forever connected. Audere est Facere.'


BreakingNews.ie
14 minutes ago
- BreakingNews.ie
A-ha singer Morten Harket announces Parkinson's disease diagnosis
A-ha's lead singer Morten Harket has announced his diagnosis with Parkinson's disease. The frontman of the Norwegian synth-pop group, known for hits including Take On Me and You Are The One, said he is having issues with his voice due to the condition, which causes parts of the brain to become progressively damaged over many years. Advertisement His bandmate Magne Furuholmen has said all future A-ha-related activities 'will of course be tuned to suit Morten's situation'. View this post on Instagram A post shared by a-ha (@officialaha) Speaking to a biographer for an article on the A-ha website, Harket, 65, said: 'I've got no problem accepting the diagnosis. With time I've taken to heart my 94-year-old father's attitude to the way the organism gradually surrenders: 'I use whatever works'.' He continued: 'Acknowledging the diagnosis wasn't a problem for me; it's my need for peace and quiet to work that has been stopping me. 'I'm trying the best I can to prevent my entire system from going into decline. Advertisement 'It's a difficult balancing act between taking the medication and managing its side effects. 'There's so much to weigh up when you're emulating the masterful way the body handles every complex movement, or social matters and invitations, or day-to-day life in general.' Harket underwent a neurosurgical procedure in which electrodes were implanted deep inside the left side of his brain in June 2024 and had a similar procedure on the right side of his brain in December 2024, according to the website article. Magne Furuholmen, Morten Harket and Pal Waaktaar of A-ha during a signing session at HMV Oxford Street, London (Yui Mok/PA) These electrodes are connected to a small pacemaker-like device placed under the skin of the upper chest that sends electrical impulses through the electrodes into the brain and this method of treatment is called deep brain stimulation (DBS). Advertisement There is currently no cure for Parkinson's disease but there are treatments like physiotherapy and medication, according to the NHS website. The main symptoms are tremors, slow movement and stiff and inflexible muscles, and Harket also said the condition has affected his voice. 'The problems with my voice are one of many grounds for uncertainty about my creative future,' he said. Asked if he can sing at the moment, he said: 'I don't really know. I don't feel like singing, and for me that's a sign. Advertisement 'I'm broadminded in terms of what I think works; I don't expect to be able to achieve full technical control. The question is whether I can express myself with my voice. 'As things stand now, that's out of the question. But I don't know whether I'll be able to manage it at some point in the future.' He added: 'For a few years now I've been working on songs that I've got great belief in, and I feel the lyrics, especially, have something of a different aspect of me in them. 'I'm not sure if I'll be able to finish them for release. Time will tell if they make it. Advertisement 'I really like the idea of just going for it, as a Parkinson's patient and an artist, with something completely outside the box. It's all up to me, I just have to get this out of the way first.' A-ha formed in Oslo in 1982, comprised of guitarist Paul Waaktaar-Savoy, keyboardist Furuholmen and lead singer Harket. The band has had nine top 10 singles in the UK chart, including chart-topping track The Sun Always Shines On TV, and seven top 10 albums. Furuholmen said in an Instagram post on Wednesday: 'It is a day of sad news in a-ha world. Having known about Morten's diagnosis for some time does not take the force out of the blow, nor diminish the impact it has had, and will continue have, on us – as people and as a band. Morten Harket on stage at the Brit Awards 2006 (Yui Mok/PA) 'Our thoughts are first and foremost with Morten and his family at a difficult time adjusting to the changes that this condition has brought into their lives. 'As the news brings sadness, it is worth to remember through the hurt that there is also a lot of gratitude: for all the amazing memories, for how our combined creative efforts as a band have been so generously embraced by the world, and for how lucky we are that people continue to find meaning, hope and joy in our shared musical legacy. 'All future a-ha-related activities will of course be tuned to suit Morten's situation, but together we will work to try and find ways to give you the best of ourselves. Thank you everyone for all your support, your kind words, and consideration.'


The Independent
17 minutes ago
- The Independent
Home Office plans to spend £2.2bn of foreign aid on asylum support this year
The Home Office plans to spend about £2.2 billion of foreign aid to support asylum seekers this financial year, according to new figures. The amount of overseas development assistance (ODA) budgeted by the Home Office – which is largely used to cover accommodation costs such as hotels for asylum seekers – is slightly less than the £2.3 billion it spent in 2024/25. International rules allow countries to count first-year costs of supporting refugees as overseas development assistance (ODA). The figures, first reported by the BBC, were published in recent days on the Home Office website. The Home Office said it is 'urgently taking action to restore order and reduce costs' which will cut the amount spent to support asylum seekers and refugees in the UK. It also said it was expected to have saved £500 million in asylum support costs in the last financial year, and that this had saved £200 million in ODA which had been passed back to the Treasury. A total of 32,345 asylum seekers were being housed temporarily in UK hotels at the end of March this year. This figure is down 15% from the end of December, when the total was 38,079, and 6% lower than the 34,530 at the same point a year earlier. Asylum seekers and their families are housed in temporary accommodation if they are waiting for the outcome of a claim or an appeal and have been assessed as not being able to support themselves independently. They are housed in hotels if there is not enough space in accommodation provided by local authorities or other organisations. Labour has previously said it is 'committed to end the use of asylum hotels over time', adding that under the previous Conservative government at one stage 'more than 400 hotels were in use and almost £9 million per day was being spent'. Jo White, chairwoman of the Red Wall group of Labour MPs, told BBC Radio 4's Today programme on Saturday: 'We need to be looking at things like ECHR article eight. I don't think anything's off the table … including looking at new options such as processing abroad. 'So, we have to be open to see how we can move move that backlog as quickly as possible. I'm getting impatient. 'I know my colleagues in parliament are getting impatient and we're pressing the Government as hard as we can on this.' A Home Office spokesperson said: 'We inherited an asylum system under exceptional pressure and are urgently taking action to restore order and reduce costs. 'This will ultimately reduce the amount of official development assistance spent to support asylum seekers and refugees in the UK. 'We are immediately speeding up decisions and increasing returns so that we can end the use of hotels and save the taxpayer £4 billion by 2026. 'The Rwanda scheme also wasted £700 million to remove just four volunteers – instead, we have surged removals to nearly 30,000 since the election, are giving law enforcement new counter-terror style powers, and increasing intelligence sharing through our Border Security Command to tackle the heart of the issue, vile people-smuggling gangs.'